Predict your next investment

Venture Capital
sofinnova.com

See what CB Insights has to offer

Investments

329

Portfolio Exits

111

Funds

13

Service Providers

3

About Sofinnova Ventures

Sofinnova Ventures has partnered with entrepreneurs to secure initial funding, build successful management teams, form impactful corporate alliances, win key customers, and navigate acquisitions and IPOs. The firm applies capital and expertise to guide start-up companies to successful exits.

Sofinnova Ventures Headquarter Location

3000 Sand Hill Road 4-250

Menlo Park, California, 94025,

United States

650-681-8420

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Sofinnova Ventures News

Antiva Biosciences Closes $31 Million Series D Equity Financing

Nov 3, 2021

Antiva Biosciences Closes $31 Million Series D Equity Financing Financing Supported by Syndicate of Premier Life Science Investors Led by Adjuvant Capital and Including GV, HBM, Canaan, and Sofinnova, Among Others Proceeds to Support Continued Development of ABI-2280, Including Near-Term Advancement into Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif., November 2, 2021-- Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $31 million Series D equity financing. The financing was supported by a syndicate of premier life science investors led by Adjuvant Capital, a leading global and women's health venture firm, and joined by GV, formerly Google Ventures. Participants in the financing also included new investors HBM Healthcare Investments, Avestria Ventures, Gaingels and Mana Ventures, as well as existing investors including Canaan Partners, Sofinnova Ventures, Lumira Ventures, Brace Pharma Capital, Sirona Capital, Osage University Partners, Dong-A ST and Alexandria Venture Investments. In conjunction with the financing, Jenny Yip, Managing Partner, Adjuvant Capital, will join Antiva's board of directors. Proceeds from the financing will support the continued development of the company's lead development candidate, ABI-2280, including the near-term advancement of the compound into Phase 1 and 2a clinical trials as a potential treatment for high-grade cervical intraepithelial neoplasias (HSIL, CIN 2,3). ABI-2280 is a prodrug of an acyclic nucleoside phosphonate with known potent antiviral activity which works by directly blocking HPV replication and inducing apoptosis in HPV-infected lesions, while sparing normal cells. Antiva has leveraged its development expertise to create a topical formulation of the compound that is rapidly taken up into epithelial cells, avoiding the potential systemic toxicity often seen when potent antiviral drugs are delivered systemically. The company intends to initiate a Phase 1 clinical trial of ABI-2280 during the fourth quarter, with data expected in the first half of 2022. "This round of financing comes at an active and exciting time for Antiva, as we rapidly approach the initiation of our first-in-human Phase 1 clinical trial of ABI-2280. With industry-wide interest continuing to grow in the global health and women's health sectors, we feel that ABI-2280 is strongly positioned to meet several critical unmet needs in these areas," said Gail Maderis, President and CEO of Antiva. "As a non-surgical treatment, ABI-2280 has the potential to offer a therapeutic that can preserve women's reproductive health, be self-administered at home, and improve access to care in underserved communities where OB/GYN resources are scarce. These attributes are particularly valuable in lower- and middle-income countries (LMIC) , which account for the majority of the more than 300,000 annual deaths from cervical cancer worldwide." "As an investor targeting companies tackling high-burden public health challenges in historically overlooked market segments, we feel that Antiva fits our investment approach perfectly. By leveraging a novel technology to develop a topical treatment for HPV-related diseases that often progress into invasive cancers, Antiva is working to address a major global unmet clinical need with a goal of increasing treatment access to women throughout the world," said Ms. Yip. "We are proud to support the company's efforts in this area and look forward to the ongoing development of ABI-2280 as it enters the clinic." In conjunction with the close of the Series D financing, Antiva and Adjuvant are establishing a global health committee designed to accelerate global development and commercialization of ABI-2280 in lower and middle income countries. The committee will be led by Clifford Samuel, a member of Antiva's board of directors and formerly Senior Vice President of Global Patient Solutions at Gilead, who brings more than two decades of experience developing and commercializing global health therapeutics. About HPV-Related Diseases and Cervical Cancer Human Papilloma Virus (HPV) is so common that nearly all sexually active men and women are infected with the virus at some point in their lives. While many of these are transient infections which the body is capable of fighting off, the infections that persist are known to drive the formation of malignancies, including cervical, anal, vulvar, penile, and head and neck cancers. The introduction of prophylactic vaccines for HPV was a major step forward in the fight against HPV-associated cancers by preventing infection by certain high-risk HPV subtypes. However, due to low adoption rates in the US, EU, and Japan, and limited access to the vaccines in developing countries, HPV infections and the disease states driven by such infections remain a major unmet clinical need. Globally, cervical cancer is the fourth most common cancer in women and as such represents a major public health problem. According to the World Health Organization, an estimated 570,000 women were diagnosed with cervical cancer worldwide and approximately 311,000 women died from the disease in 2018. About Antiva Biosciences Antiva Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. The company, based in South San Francisco, was founded in 2012 by Dr. Karl Hostetler of The University of California San Diego. The company's lead drug candidate, ABI-2280 is initially being developed as a topical treatment for high-grade cervical intraepithelial neoplasias (HSIL, CIN 2,3). Antiva believes that development of ABI-2280 may also be expanded to include other pre-cancers attributed to HPV, such as vulvar (VIN 2,3) and anal (AIN 2,3) neoplasias. For more information, please visit: www.antivabio.com. Contact:

Sofinnova Ventures Investments

329 Investments

Sofinnova Ventures has made 329 investments. Their latest investment was in Antiva Biosciences as part of their Series D on November 11, 2021.

CBI Logo

Sofinnova Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/2/2021

Series D

Antiva Biosciences

$31M

No

6

10/26/2021

Series C

Quanta Therapeutics

$60M

Yes

3

10/12/2021

Series B

CinCor Pharma

$143M

No

10

3/26/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/22/2021

Series A - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/2/2021

10/26/2021

10/12/2021

3/26/2021

3/22/2021

Round

Series D

Series C

Series B

Series C

Series A - III

Company

Antiva Biosciences

Quanta Therapeutics

CinCor Pharma

Subscribe to see more

Subscribe to see more

Amount

$31M

$60M

$143M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

6

3

10

10

10

Sofinnova Ventures Portfolio Exits

111 Portfolio Exits

Sofinnova Ventures has 111 portfolio exits. Their latest portfolio exit was CinCor Pharma on January 07, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/7/2022

IPO

$99M

Public

4

12/22/2021

Acquired

$99M

19

7/15/2021

Reverse Merger

$99M

2

6/30/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/14/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/7/2022

12/22/2021

7/15/2021

6/30/2021

5/14/2021

Exit

IPO

Acquired

Reverse Merger

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

4

19

2

10

10

Sofinnova Ventures Fund History

13 Fund Histories

Sofinnova Ventures has 13 funds, including Sofinnova Venture Partners X.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/17/2016

Sofinnova Venture Partners X

Multi-Stage Venture Capital

Closed

$650M

2

7/23/2014

Sofinnova Venture Partners IX

Multi-Stage Venture Capital

Closed

$500M

2

3/21/2012

Sofinnova Ventures Ireland Life Sciences Investment Fund

Early-Stage Venture Capital

Open

$38M

1

10/17/2011

Sofinnova Venture Partners VIII LP

Subscribe to see more

Subscribe to see more

$99M

10

10/31/2006

Sofinnova Ventures VII LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/17/2016

7/23/2014

3/21/2012

10/17/2011

10/31/2006

Fund

Sofinnova Venture Partners X

Sofinnova Venture Partners IX

Sofinnova Ventures Ireland Life Sciences Investment Fund

Sofinnova Venture Partners VIII LP

Sofinnova Ventures VII LP

Fund Type

Multi-Stage Venture Capital

Multi-Stage Venture Capital

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Open

Subscribe to see more

Subscribe to see more

Amount

$650M

$500M

$38M

$99M

$99M

Sources

2

2

1

10

10

Sofinnova Ventures Service Providers

3 Service Providers

Sofinnova Ventures has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Subscribe to see more

Service Type

General Counsel

Partnership data by VentureSource

Sofinnova Ventures Team

12 Team Members

Sofinnova Ventures has 12 team members, including current Chief Executive Officer, President, General Partner, Alain Azan.

Name

Work History

Title

Status

Alain Azan

Chief Executive Officer, President, General Partner

Current

Nathalie Auber

Chief Financial Officer

Current

Debbie Murray

Chief People Officer

Current

Anand Mehra

Managing General Partner

Current

James Healy

Managing Partner

Current

Name

Alain Azan

Nathalie Auber

Debbie Murray

Anand Mehra

James Healy

Work History

Title

Chief Executive Officer, President, General Partner

Chief Financial Officer

Chief People Officer

Managing General Partner

Managing Partner

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.